Drug Profile
Research programme: proteasome inhibitors - Bristol-Myers Squibb
Alternative Names: 20S proteasome inhibitors - Bristol-Myers SquibbLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; NF-kappa B inhibitors; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 18 May 2007 Preclinical trials in Cancer in USA (unspecified route)